Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
about
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsMATE2 Expression Is Associated with Cancer Cell Response to MetforminPharmacogenomics in type 2 diabetes: oral antidiabetic drugs.The role of variants regulating metformin transport and action in women with polycystic ovary syndrome.Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.An update on the pharmacogenomics of metformin: progress, problems and potential.Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in nPharmacogenetics of oral antidiabetic drugs.Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.The pharmacogenetics of type 2 diabetes: a systematic review.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Genetics of drug response in type 2 diabetes.Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine.Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients.Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian populationDifferential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.The pharmacogenetics of metformin.A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes.Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.
P2860
Q26751138-D1F7C97D-C5E7-414F-8AD5-C1C8B57466DCQ28555000-25A56FAE-206C-4DA7-B931-80861D0B1393Q30248914-C074C1D8-A5F4-45D1-BFF2-A4C6EB214E25Q30275579-36D9C652-1E28-4457-8275-1191AC103EEFQ33658321-67C3142C-2534-4663-92E3-4F6A7D20E621Q33804241-75729EAF-DA82-417E-85E1-CFB626BDDA1EQ34003050-E9AD66EF-CA9C-4CB1-8772-FD5FE87EB4D3Q36095402-010D2DCD-4EC4-4533-BC11-0D26CA22D023Q36610479-45D43ACB-99B6-427F-94F1-BFD1CCD2B80EQ36924379-7396FB27-7793-404F-B81E-AF6BE4A78C6AQ37222650-E667C27B-8484-44B0-8655-5C75701A3732Q37230961-3A6FF8B8-26E8-4CD6-A1EB-2429DE9B679BQ37353476-7EB36723-A9C3-45B8-9569-45160EED8D57Q37571899-38218A7D-1944-4D81-A68B-0DB96DF43762Q37597017-668F34D6-3A91-4BCD-A004-A3BB0EE0896FQ38110432-D2F90068-7D87-4525-B341-456DF553F557Q38480670-48839385-EA0F-4DA4-B371-1F187B55CACEQ38622785-426E5C0B-AB54-40F4-93D2-8FE5803A4EFFQ38747416-6258A7BF-1F34-4D54-B89F-457D4088D1F7Q38816602-EC60D354-06DF-43CA-8E2A-8466A138271BQ38831370-548163B8-F300-47B1-BD9C-47180489D080Q38831752-7FBCA8BC-A1B9-4CBA-9060-F63FB66C0D4EQ38844658-9FF6E4C6-5E8B-47B2-8C89-1DA6E83B60CBQ39031270-69447020-3D11-4AD5-B659-76E5F41D7F51Q41170648-4D0C15BC-763D-4FA7-98BB-955AACBDECBFQ41709049-CBDB3358-3FDE-4765-A12E-B62F584E91EBQ42106306-CE509753-8FF8-4946-AADB-D254A3749F5EQ48099965-888CFA9F-C597-4D6F-9DF9-494ED66669ADQ48226343-80F8F607-5D06-428D-BBA1-2A71B71AD7A5Q48610822-B024A86B-DDF0-4C0A-8D28-75A6BC2FBD4FQ48821218-8CDD8595-12B6-4715-A4C6-1E28D86B0BC1Q53641711-1BA985F7-9AFF-4ABD-92CF-8793AE06E306Q55052487-D344463A-D211-49A7-99EA-1748C50399AF
P2860
Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@en
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@nl
type
label
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@en
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@nl
prefLabel
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@en
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@nl
P2093
P2860
P921
P1476
Pharmacogenomic association be ...... metformin in type 2 diabetes.
@en
P2093
E Babjaková
H Hermanová
L Klimčáková
M Fabianová
M Javorský
Z Schroner
P2860
P304
P356
10.1111/J.1463-1326.2012.01691.X
P577
2012-09-09T00:00:00Z